Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

Public hospitals in two Australian states acquire GreenLight HPS laser consoles for BPH treatment

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced that eight GreenLight HPS® laser consoles have been acquired for public hospitals in the Australian states of Victoria and Queensland. The laser technology will treat patients with Benign Prostatic Hyperplasia (BPH), a non cancerous enlargement of the prostate experienced by 50 percent of men over 60.

4 Oct 2010

VIVUS announces divestiture of MUSE to Meda

VIVUS, Inc. today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED). Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

4 Oct 2010

Meda announces acquisition of global rights to erectile dysfunction product MUSE

Meda today announced the acquisition of global rights to MUSE (transurethral alprostadil), a well established product for the treatment of erectile dysfunction.

4 Oct 2010

Researchers find gene variations in PDE11A enzyme can increase risk for prostate cancer

Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.

4 Oct 2010

AMS reports 12-month study results of Elevate Apical and Posterior Prolapse Repair System

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System. The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.

22 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Apricus Biosciences, backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that results from a United States Pharmacopeia Preservative Efficacy Test (USP PET) qualified NexACT as an anti-microbial preservative. The results show that NexACT was effective in killing more than 23 strains of bacteria, fungus and mold, well beyond the requirements for passing the USP PET.

21 Sep 2010

Johns Hopkins offers sources who can answer queries on prostrate cancer

September 19-25 is National Prostate Cancer Awareness Week. If you are planning a story on prostate cancer, a disease that's diagnosed in more than 200,000 American men each year, please consider calling on experts from the Johns Hopkins Brady Urological Institute.

16 Sep 2010

AMS receives favorable ruling in Davenport infringement lawsuit

American Medical Systems Holdings, Inc., a leading provider of world-class devices and therapies for male and female pelvic health, announced today that the company is pleased with yesterday's U.S. Court of Appeals for the Federal Circuit's ruling that reversed a summary judgment and finding for Biolitec, Inc.

15 Sep 2010

Over half of men surveyed believe erectile dysfunction as a symptom of overall health

A new poll of men and women over 50 years old reveals that, while most men report some level of erectile dysfunction (ED), women generally aren't aware of the problem in their partners. The problem extends beyond simple communication since ED can often be a symptom of overall health and well-being in men.

14 Sep 2010

Campaign for Tobacco-Free Kids applauds FDA for action against electronic cigarette distributors

We applaud the U.S. Food and Drug Administration for taking appropriate enforcement action today against five distributors of electronic cigarettes for various violations of the Federal Food, Drug and Cosmetic Act (FDCA), including unsubstantiated claims and poor manufacturing practices.

10 Sep 2010

FDA issues warning letters to five electronic cigarette distributors

The U.S. Food and Drug Administration today issued warning letters to five distributors for various violations of the Federal Food, Drug, and Cosmetic Act (FDCA) including unsubstantiated claims and poor manufacturing practices.

10 Sep 2010

More support needed for erectile dysfunction says sexologist

According to sexologist Bettina Arndt, there are thousands of Australian men with erectile dysfunction who are sexually impotent because of their condition and the lack of affordable treatments. Arndt said that funds distribution for breast prostheses for female cancer patients is one of the examples of mismatches in funding.

3 Sep 2010

Agent Orange cases expanded; Added costs raise fiscal concerns

Hundreds of thousands of Vietnam War veterans are receiving disability compensation for diseases normally associated with aging - not combat - because of the possibility of a link Agent Orange exposure. The diseases in question range from diabetes, for which 270,000 veterans receive Agent Orange-related checks, to erectile dysfunction.

2 Sep 2010

VA prepares to expand Agent Orange related claims for Vietnam veterans

The Washington Post: "The Department of Veterans Affairs is preparing for more than 150,000 Vietnam War veterans to apply for benefits in the next 18 months thanks to new regulations making it easier to compensate for health problems caused by exposure to the Vietnam-era defoliant Agent Orange. Changes set for publication in Tuesday's Federal Register could result in payouts of about $42 billion in the next decade, VA said.

2 Sep 2010

LadyBug Resource Group to acquire Men's Medical Corporation

LadyBug Resource Group Inc. has signed an Agreement to acquire 100% of Men's Medical Corporation.

31 Aug 2010

Study finds sexual problem common among diabetic patients

Many middle-aged and older adults with diabetes are sexually active according to a study of nearly 2,000 people aged 57 to 85 presented in the September 2010 issue of the journal Diabetes Care. Almost 70 percent of partnered men with diabetes and 62 percent of partnered women with diabetes engaged in sexual activity two or three times a month, comparable to those without diabetes, the study showed.

27 Aug 2010

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

NexMed, Inc., backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that the Israel Patent Office has issued an allowance notice for NexMed's patent application entitled, "Topical Compositions for Prostaglandin E1 Delivery."

24 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Prostate cancer updates

Public hospitals in two Australian states acquire GreenLight HPS laser consoles for BPH treatment

VIVUS announces divestiture of MUSE to Meda

Meda announces acquisition of global rights to erectile dysfunction product MUSE

Researchers find gene variations in PDE11A enzyme can increase risk for prostate cancer

AMS reports 12-month study results of Elevate Apical and Posterior Prolapse Repair System

VIVUS announces QNEXA study results for obesity treatment

USP PET results qualify Apricus Bio's NexACT as anti-microbial preservative

Johns Hopkins offers sources who can answer queries on prostrate cancer

AMS receives favorable ruling in Davenport infringement lawsuit

Over half of men surveyed believe erectile dysfunction as a symptom of overall health

Campaign for Tobacco-Free Kids applauds FDA for action against electronic cigarette distributors

FDA issues warning letters to five electronic cigarette distributors

More support needed for erectile dysfunction says sexologist

Agent Orange cases expanded; Added costs raise fiscal concerns

VA prepares to expand Agent Orange related claims for Vietnam veterans

LadyBug Resource Group to acquire Men's Medical Corporation

Study finds sexual problem common among diabetic patients

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Innovation in neuroscience drug discovery - eBook eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in